Marc L Gordon, Md

This pilot study tested daratumumab, a cancer drug, in 16 people with mild to moderate Alzheimer's disease. The goal was to see if it could improve thinking and memory. The study was small and open-label, meaning everyone knew they were getting the drug, so results are very early…